NYSE:MYOV
Delisted
Myovant Sciences Ltd Stock News
$26.98
+0 (+0%)
At Close: Jun 08, 2023
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Myovant Sciences (MYOV) Reports Q4 Loss, Misses Revenue Estimates
12:05pm, Tuesday, 10'th May 2022 Zacks Investment Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -14.55% and 5.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
10:55am, Tuesday, 10'th May 2022 GlobeNewswire Inc.
BASEL, Switzerland, May 10, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, e
Myovant Sciences (MYOV) Reports Q4 Loss, Misses Revenue Estimates
09:47am, Tuesday, 10'th May 2022
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -14.55% and 5.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
10:30am, Monday, 09'th May 2022 GlobeNewswire Inc.
BASEL, Switzerland and HARROW, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Accord Healthcare, Ltd. (Accord) today announced that they have entered into an e
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
10:45am, Friday, 06'th May 2022 GlobeNewswire Inc.
BASEL, Switzerland, and NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has exte
Will Myovant Sciences (MYOV) Report Negative Earnings Next Week? What You Should Know
07:00pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Myovant Sciences (MYOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Myovant Sciences (MYOV) Report Negative Earnings Next Week? What You Should Know
04:33pm, Tuesday, 03'rd May 2022
Myovant Sciences (MYOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
07:49pm, Monday, 02'nd May 2022 Benzinga
Myovant Sciences Ltd (NYSE: MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
04:05pm, Monday, 02'nd May 2022
Myovant Sciences Ltd (NYSE: MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
11:10pm, Friday, 29'th Apr 2022 GlobeNewswire Inc.
BASEL, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVY
Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates
09:45pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 24.49% and 4.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant: Poised To Overcome Regulatory Issues
12:16pm, Tuesday, 26'th Apr 2022
The steep decline in Myovant Sciences share price is due to an FDA notice regarding relugolix label expansion for endometriosis. Irrespective of the FDA decision, I strongly believe that relugolix wil
BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results for
Myovant Sciences provides an update on a supplemental new drug
11:03am, Saturday, 16'th Apr 2022
Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced an update for an sNDA for MYFEMBREE, which is designed to manage severe to moderate pain linked to endometriosis. According to the ong
